What Rapport Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 11 | 11 |
| Sells | 15 | 66 |
| Total trades | 28 | 83 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 2,459,745 | 2,479,745 |
| Disposed | 96,637 | 1,184,718 |
| Net activity | +2,363,108 | +1,295,027 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.p. | Director | Oct 30 | Grant / award · A | +1,190,476 | $21.00 | +$25M | 2,159,694 |
| Third Rock Ventures V, L.p. | Director | Oct 30 | Grant / award · A | +238,095 | $21.00 | +$5M | 6,518,620 |
| Healy James | Director | Oct 28 | Open-market buy · P | +6,933 | $21.00 | +$146K | 25,267 |
| Healy James | Director | Oct 28 | Open-market buy · P | +3,772 | $21.00 | +$79.2K | 14,924 |
| Healy James | Director | Oct 28 | Open-market buy · P | +6,395 | $21.00 | +$134K | 17,990 |
| Healy James | Director | Oct 28 | Open-market buy · P | +952,380 | $21.00 | +$20M | 2,815,707 |
| Sanchez Ramiro | Director | Oct 23 | Open-market buy · P | +3,600 | $27.35 | +$98.5K | 3,600 |
| Young Wendy B. | Director | Oct 22 | Open-market buy · P | +3,789 | $26.39 | +$100K | 13,289 |
| Paul Steven M | Director | Oct 22 | Open-market buy · P | +35,714 | $27.28 | +$974K | 77,380 |
| Maraganore John | Director | Oct 22 | Open-market buy · P | +1,172 | $26.92 | +$31.5K | 9,411 |
| Maraganore John | Director | Oct 22 | Open-market buy · P | +8,239 | $26.38 | +$217K | 8,239 |
| Silva Paul M | Director | Oct 22 | Open-market buy · P | +3,680 | $27.08 | +$99.6K | 3,680 |
| Ignelzi Troy A. | Chief Financial Officer | Oct 21 | Open-market buy · P | +5,500 | $26.10 | +$144K | 15,500 |
| Ceesay Abraham | Chief Executive Officer | Oct 21 | Open-market sale · S | −2,210 | $29.16 | −$64.4K | 450,035 |
| Ceesay Abraham | Chief Executive Officer | Oct 07 | Open-market sale · S | −1,147 | $30.66 | −$35.2K | 452,245 |
| Ceesay Abraham | Chief Executive Officer | Oct 06 | Open-market sale · S | −3,375 | $32.03 | −$108K | 453,392 |
| Gault Cheryl | Chief Operating Officer | Sep 30 | Open-market sale · S | −2,075 | $33.76 | −$70K | 139,914 |
| Gault Cheryl | Chief Operating Officer | Sep 30 | Open-market sale · S | −7,925 | $33.04 | −$262K | 141,989 |
| Ceesay Abraham | Chief Executive Officer | Sep 23 | Open-market sale · S | −43 | $41.05 | −$1.77K | 456,767 |
| Ceesay Abraham | Chief Executive Officer | Sep 23 | Open-market sale · S | −215 | $39.86 | −$8.57K | 456,810 |
Loading...